Contraindications and Precautions for Bonjela Paste (Choline Salicylate)
Bonjela paste containing choline salicylate is absolutely contraindicated in children under 16 years of age with viral infections (varicella or influenza-like illness) due to the risk of Reye syndrome, and should be avoided in children under 12 years generally due to increased risk of salicylate toxicity.
Critical Pediatric Contraindications
The most serious concern with choline salicylate use involves Reye syndrome risk in children. Based on salicylate class evidence:
- Absolute contraindication: Children with varicella (chickenpox) or influenza-like illnesses 1
- Strong precaution: All children under 12 years of age due to increased systemic absorption risk and salicylate toxicity 1
- Mechanism: Salicylates in children with viral infections are associated with Reye syndrome development, a potentially fatal condition 2
The evidence shows salicylate consumption correlates with both occurrence and severity of Reye syndrome in a dose-dependent manner 2.
Systemic Absorption and Toxicity Risk
Salicylate toxicity can occur from topical application, particularly in high-risk populations:
High-Risk Scenarios:
- Application to >20% body surface area 3
- Patients with abnormal hepatic or renal function 3
- Prolonged or excessive use in any patient 1
- Children under 2 years (higher concentrations like 6% formulations) 1
Clinical Pitfall:
Oral mucosa has enhanced absorption compared to intact skin. Even small amounts applied to oral tissues can result in measurable systemic salicylate levels 4, 5.
Absolute Contraindications
Known hypersensitivity to salicylic acid, choline salicylate, or any formulation ingredient 1
Concurrent salicylate therapy: Do not combine with other oral or topical salicylate drugs (aspirin, other NSAIDs) due to additive toxicity risk 1, 3
Children with active viral infections (varicella, influenza) at any age 1
Pregnancy and Lactation
Pregnancy Category C for salicylates 1:
- Generally avoid unless benefit clearly outweighs risk
- Absolutely discontinue 6-8 weeks before term to prevent:
- Prolonged gestation and labor
- Increased peripartum bleeding
- Premature ductus arteriosus closure in fetus
- Fetal pulmonary hypertension
- Impaired fetal renal function 6
Breastfeeding:
- Discontinue nursing or the drug 1
- Salicylates displace bilirubin - absolutely contraindicated when breastfeeding neonates with jaundice 6
- Risk of salicylate intoxication and bleeding in neonate 6
Drug Interactions
Avoid concurrent use with 1:
- Anticoagulants (warfarin) - increased bleeding risk 7
- Antidiabetic agents
- Corticosteroids
- Diuretics
- Methotrexate
- Other NSAIDs/aspirin
Adverse Effects to Monitor
Common local effects 1:
- Hypersensitivity reactions
- Excessive erythema
- Scaling
- Contact dermatitis 7
- Anaphylactic reactions (rare) 7
Systemic toxicity signs (requires immediate discontinuation):
- Tinnitus
- Hearing loss
- Nausea/vomiting
- Confusion
- Hyperventilation
Special Populations Algorithm
For children:
- Age <12 years: Avoid use
- Age 12-16 years with viral illness: Absolute contraindication
- Age >16 years: May use with caution, limit application area
For pregnant women:
- First/second trimester: Use only if essential
- Third trimester (especially last 6-8 weeks): Contraindicated
For patients on anticoagulation:
- Avoid - risk of enhanced anticoagulation and bleeding 7
For patients with hepatic/renal impairment:
- Use with extreme caution or avoid - increased systemic absorption risk 3
Practical Application Guidelines
- Limit treatment area to minimize systemic absorption
- Monitor for signs of salicylate toxicity in all patients, especially children
- Avoid prolonged use (>7 days without medical supervision)
- Do not apply to large areas of oral mucosa simultaneously
- Screen for concurrent salicylate use before prescribing